Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465517 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
A Phase 2 study, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT00465517 is a Phase 2 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 147 participants.
The verdict
NCT00465517, a Phase 2 study, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs). The study will also evaluate the effectiveness of ganaxolone in females with catamenial epilepsy. Catamenial epilepsy refers to a relationship between seizure frequency and a woman's menstrual cycle, where the number of seizures increases around the time of a woman's menstrual cycle.
Interventions
- OTHER Placebo
- DRUG Ganaxolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465517
The ClinicalTrials.gov registry entry for NCT00465517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00465517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465517 about?
NCT00465517 is a clinical study titled "A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures". The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs). The study will also evaluate the effectiveness of ganaxolone in females with catamenial epilepsy. ...
What is the current status of trial NCT00465517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2007-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00465517?
The interventions under investigation include: Placebo (OTHER), Ganaxolone (DRUG).
Who is sponsoring clinical trial NCT00465517?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.